**Clinical Data**

|  |  |
| --- | --- |
| Demographics (DM) | Visit 2 date, age, sex, race, ethnicity, cohort status (i.e. 1 healthy, 2 MCI, 3 Probable AD), date of core study completion/withdrawal/discontinuation, |
| Subject Characteristics (SC) | Hand dominance, marital status, years of education, occupation, type of residencefamily history of AD, biological mother with AD and age at diagnosis, biological father with AD and age at diagnosis, biological sibling with AD and age at diagnosis, biological maternal grandmother with AD and age at diagnosis, biological paternal grandfather with AD and age at diagnosis, biological child with AD and age at diagnosis |
| Disposition (DS) | Supplementary note if no signed informed consent prior to study procedures,participant informed consent date and time, study partner informed consent date and time, participation in the optional RetiSpec Retinal ScanCompletion/discontinuation reason, date of core study completion/withdrawal/discontinuationReferral to studies (and which ones) after the Bio-Hermes core study, consent to another (and which) study after Bio-Hermes coreUpdates to informed consent at visit 3 |
| Inclusion Exclusion Criteria Not Met (IE) | Eligibility, reason for screenfail (inclusion and exclusion criteria) |
| Adverse Events (AE) | AE term (diagnosis if known), onset date and time, AE ongoing at the end of the study, end date and time, withdrawal due to AE or Serious AE (SAE), event severity, outcome of event, other action taken, was this an SAE, resulted in death, immediately life threatening, requires inpatient hospitalization or prolongation of existing hospitalisation, created persistent or significant disability or incapacity, is a congenital anomaly or birth defect, supplementary SAE notes |
| Substance Use (SU) | Alcohol use, alcohol history, end date of previous alcohol use, tobacco use, tobacco history, end date of previous tobacco use |
| Nervous System Findings (NV) | Was amyloid PET scan performed, date and time of scan, amyloid PET results (positive/negative) and specification if noPET disclosure to participant, date and time, participant declined PET disclosure after meaningful discussion,  |
| BioSpecimen Findings (BS) | Lumbar puncture (LP) for CSF collection, date and time of LP, volume of SCF collected, number of cryo vials placed in the freezer, CSF barcode on label,  |
| Related Records | CSF barcode on label |
| Concomitant/Prior Medications (CM) | Medication name, primary indication, dose, unit, frequency, route, start date, stop date, ongoing |
| Medical History (MH) | Positive COVID-19 test and date Medical condition name, start and stop date, ongoing at the end of the studyCurrent AD diagnosis (N/A, MCI, probably AD), date of diagnosis for MCI and AD, was MCI and AD diagnosis within 3 months of screening, stage of initial diagnosis, date of first symptoms observed |
| Procedures (PR) | Surgery or procedure name and date, performed prior to the study (Y/N) |
| Functional Tests (FT) | Mini Mental State Examination (MMSE): completion date, start and stop time. Correctness of responses for: orientation to time (year, season, month of the year, day of the week, date), orientation to place (state, county, city/town, building, floor of the building), registration (apple, penny, table), attention and calculation (93, 86, 79, 72, 65), recall (apple, penny, table), naming (pencil, watch), repetition (no ifs, ands, or buts), comprehension (take in right hand, fold in half, put on floor), reading (close your eyes), writing (please write a sentence), drawing (please copy this design),MMSE total score.Rey Auditory Verbal Learning Test (RAVLT): completion date, start and stop time, scores I-V and total score I-V, Score B, Score Short Delay, End of Short Delay Time, start of long delay time, score long delay, score true and false positives, adjusted T scoreCognitive Clarity for Cognitive Assessments (CCCA): completion date, start and stop time, start and stop time of 20-minute breakLinus Platform tests (see partner data table below): completion date, start and stop time |
| Disease Response and Clinical Classification (RS) | Functional Activities Questionnaire (FAQ): completion date, start and stop time, and score for: writing checks, paying bills, balancing checkbook,Assembling tax records, business affairs, or papers,Shopping alone for clothes, household necessities, or groceries,Playing a game of skill, working on a hobby,Heating water, making a cup of coffee, turning off stove after use,Preparing a balanced meal, Keeping track of current events,Paying attention to, understanding, discussing TV, book, magazine,Remembering appointments, family occasions, holidays, medications, Travelling out of neighborhood, driving, arranging to take busesTotal Score |
| Vital Signs (VS) | Date and time of measurement, Temperature, pulse, blood pressure systolic and diastolic, respiration rate, height, weight |
| Laboratory Test Results (LB) | Amyloid PET imaging: LP for CSF collection, date and time of LP, CSF barcode on label, ABETA 42 results, ABETA 40 results, ABETA 42/40 ratio results, low or increased risk of Alzheimer’s disease, cell count results, glucose results, protein results, PT results, INR results, Platelets resultsFor visits 1 and 3: date, complete biospecimen collection and reason if not, collection date and time, lab kit barcode number, collection and processing of all lab specimens according to lab manual and supplementary comment if not,Lipid panel results (visit 1): Triglycerides value and clinical significance, HDL cholesterol value and clinical significance, LDL cholesterol value and clinical significance |
| Comments (CO) | Pertinent notes about disclosure or the participant’s decline of disclosureNotes from testing and interview sessionInvestigator’s rationale for cohort placement |
| Questionnaires (QS) | Geriatric Depression Scale (GDS): completion date, start and stop time, total score |

**Study Partner Data**

|  |  |  |
| --- | --- | --- |
| **Testing Partner** | **Type of Biomarker** | **Tests Included** |
| Aural Analytics | Speech elicitation task performance | image description volition and score, story and object recall score, visual naming intraword pause time, sentence speaking rate, category naming verbal fluency, image description speaking rate, delayed word recall score, sentence pause rate |
| C2N | Blood-based biomarkers | Aβ40, Aβ 42, Aβ 42/40, pTau-181, pTau-217, APOE, APS |
| Cognivue | Cognitive assessment using adaptive psychophysics | Score and reaction time for: adaptive motor control, visual salience, letter discrimination, word discrimination, shape discrimination, letter memory, word memory, shape memory, motion memory |
| EMtherapro | Blood-based biomarker proteomic data | -------- |
| IXICO | PET Central Reader – Binary read with SUVr results | Amyloid classification, VisQ amyloid classification, amyloid, safety QC Grade, standard uptake value ratio |
| Lilly | Blood-based biomarkers | Aβ42/40, pTau-217, NfL, GFAP, APOE, Full Genome Sequence |
| Linus Health | Digital remote brain health screening of cognitive and motion functions | Score, reaction time and time to completion Immediate and delayed digital clock recall, B-form trails, symbol digit modalities, path finding, spiral tracing, procedural reaction time, simple reaction time.  |
| Merck | Blood-based biomarkers | Aβ40, Aβ42, Aβ40/42, NfL, GFAP, Cytokines |
| Quanterix | Blood-based biomarkers | Total Tau, pTau-181 |
| Retispec | Retinal imaging | R1-R3 score, RetiSpec score for likelihood of amyloid, overall prediction of amyloid status, comments on general and pathological findings |
| Roche Diagnostics | Blood-based biomarkers | Aβ42/40, Total Tau, pTau-181, NfL GFAP, APOE |
| Somalogic | Blood-based biomarker proteomic data | --------- |
| University of Gothenburg | Brain derived blood-based biomarkers | BD Tau, Total Tau, pTau-181, pTau-217, pTau-231, NfL, GFAP |